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Abstract
Background—We previously reported that infants who developed ASD had increased CSF in 
the subarachnoid space (i.e., extra-axial CSF) from 6–24 months of age (1). We attempt to confirm 
and extend this finding in a larger, independent sample.
Methods—A longitudinal MRI study of infants at-risk for ASD was carried out on 343 infants, 
who underwent neuroimaging at 6, 12, and 24 months; 221 were high-risk for ASD because of an 
older sibling with ASD; 122 were low-risk with no family history of ASD. Forty-seven infants 
were diagnosed with ASD at 24 months and were compared with 174 high-risk and 122 low-risk 
infants without ASD.
Results—Infants who developed ASD had significantly greater extra-axial CSF volume at 6 
months compared to both comparison groups without ASD (18% greater than high-risk infants 
without ASD; Cohen’s d=0.54). Extra-axial CSF volume remained elevated through 24 months 
(d=0.46). Infants with more severe autism symptoms had an even greater volume of extra-axial 
CSF from 6–24 months (24% greater at 6 months, d=0.70; 15% greater at 24 months, d=0.70). 
Extra-axial CSF volume at 6 months predicted which high-risk infants would be diagnosed with 
ASD at 24 months with an overall accuracy of 69% and corresponding 66% sensitivity and 68% 
specificity, which was fully cross-validated in a separate sample.
Conclusions—This study confirms and extends previous findings that increased extra-axial CSF 
is detectable at 6 months in high-risk infants who develop ASD. Future studies will address 
whether this anomaly is a contributing factor to the etiology of ASD or an early risk marker for 
ASD.
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INTRODUCTION
Autism spectrum disorder (ASD) is characterized by impairments in social communication 
and the presence of repetitive stereotyped behaviors beginning in early childhood and 
typically extending throughout life (2). ASD affects about 1–2% of children worldwide (3–
5). Younger siblings of children with ASD are at substantially increased risk for developing 
ASD and offer an important strategy to discover early risk markers in a population 
unselected for having ASD (6). There are currently no biomarkers detectable in the first year 
of life that distinguish children who develop ASD from those who do not. Moreover, studies 
of high-risk infants have demonstrated that the defining behavioral features of ASD 
generally unfold in the latter part of the first and the second years of life (7–9).
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Shen et al. (1) reported that high-risk infants who later developed ASD had increased extra-
axial cerebrospinal fluid (EA-CSF) volume from 6–24 months, which was associated with 
autism severity at 36 months. Extra-axial fluid is defined as CSF in the subarachnoid space, 
surrounding the cortical convexities (10–12). While increased EA-CSF had been previously 
associated with impaired motor function (13–16), it had not been previously examined in 
relationship to ASD. Our initial report raised the possibility that dysregulation of CSF flow 
during the first year of life may play some role in the early pathogenesis of ASD, and/or 
provide a marker of an underlying process that contributes to ASD. The importance of CSF 
and its role in brain development has been highlighted in recent years (17). Once thought to 
merely provide a protective cushion for the brain, CSF has been found to play a critical role 
in the transport of growth factors that regulate progenitor cell production (18) and neuronal 
differentiation (19). In addition, as CSF circulates through the developing brain, it removes 
inflammatory cytokines and proteins secreted by neurons that can otherwise accumulate and 
have a pathological effect on brain development (20; 21).
In this study we sought to confirm and extend these findings in a larger, independent sample 
of infants at high- and low- familial risk for ASD (HR and LR infants, respectively), as part 
of the Infant Brain Imaging Study (IBIS) (22; 23). The current study has several important 
differences and advances over the original study: (1) an independent sample; (2) multi-site 
study drawn from four clinical sites across the United States; (3) a sample size roughly seven 
times larger than the original sample; (4) a different image acquisition protocol than the 
original study (harmonized across the four IBIS sites); and (5) a fully automated image 
analysis procedure to quantify EA-CSF volume. Based on findings from Shen et al. (1), we 
hypothesized that (1) HR infants later diagnosed with ASD (HR-ASD) would show 
increased EA-CSF volume at 6 months, compared to HR and LR infants who do not develop 
ASD (HR-negative and LR-negative, respectively); (2) HR-ASD infants would show 
persistently increased EA-CSF through 24 months; and (3) increased EA-CSF would be 
associated with autism severity as well as early motor deficits.
METHODS AND MATERIALS
Participants
Infants at high and low familial risk for ASD were enrolled at four clinical sites (University 
of North Carolina, University of Washington, Washington University, and Children’s 
Hospital of Philadelphia) (23). HR infants had an older sibling with a clinical diagnosis of 
ASD, corroborated by the Autism Diagnostic Interview-Revised (ADI-R); (24). LR infants 
had a typically developing older sibling and no 1st or 2nd degree relatives with intellectual/
psychiatric disorders (9). See Supplement for full inclusion/exclusion criteria. Parents 
provided informed consent, and the institutional review boards at each site approved the 
research protocol.
Assessment
Infants were assessed at 6, 12 and 24 months with an MRI and a behavioral battery that 
included measures of cognitive development (Mullen Scales of Early Learning) (25) and 
adaptive functioning (Vineland Adaptive Scales) (26). DSM-IV-TR criteria (27) and the 
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Autism Diagnostic Observation Schedule-G (ADOS) (28) were administered to all 
participants at 24 months. The ADI-R was administered at 24 months to all parents of high-
risk infants and to all low-risk infants with clinical concerns. At 24 months, infants were 
classified as having ASD based on expert clinical judgment using DSM-IV-TR criteria (27) 
and all available clinical information, including the ADOS (28), ADI-R, and other 
behavioral measures. Further details on the assessment and diagnostic procedures can be 
found in Estes et al., 2015 (9). A small number of LR infants who met criteria for ASD 
(N=3) were excluded from the analysis because they were too few to constitute a 
comparison group and to keep the study design focused on ASD in the context of familial 
risk for ASD.
Infants were included in the analysis if the infant: (1) had a successful, high quality MRI at 
least at the initial 6 month visit; and (2) was assessed for an ASD diagnosis at the 24 month 
visit. A total of 343 infants (221 HR; 122 LR) met these criteria and were included in the 
analysis, yielding three outcome groups: [1] HR-ASD (N=47; 42 male, 5 female); [2] HR-
negative (N=174; 95 male, 79 female); and [3] LR-negative (N=122; 76 male, 46 female). 
Table 1 provides a description of participant characteristics on the primary behavioral 
measures. Table 2 lists the number of MRI scans in the analysis at 6, 12, and 24 months.
By virtue of the large sample of infants at risk, we conducted follow-up analyses to assess 
whether subgroups of HR-ASD subjects, defined on the basis of autism symptom severity, 
differed in their volume of EA-CSF. The HR-ASD group (N=47) was stratified into 
subgroups according to established, empirically derived categories on the ADOS. Lord and 
colleagues established the subgrouping algorithm, which combines the scores on two ADOS 
domains (Social Affect and Restricted, Repetitive Behaviors) to derive the cutoff threshold 
that yields reliable autism subgroups (29). We applied this same ADOS threshold (29) to 
stratify the infants in the ASD group into those with ADOS scores above the threshold 
(ASD-High subgroup; N=23) and below (ASD-Moderate subgroup; N=24). This approach is 
consistent with previous publications on this sample (9).
MRI Acquisition
Imaging data were collected during natural sleep at 6, 12, and 24 months (Table 2). T1- and 
T2-weighted scans (1mm3 voxels) were acquired. Description of the MRI acquisition, 
neuroradiological review, quality control, and cross-site reliability are detailed in a previous 
publication on this sample (22) and the Supplement.
Image Analysis and Quantification of Extra-axial CSF and Lateral Ventricles
In our earlier study, segmentation of EA-CSF was carried out manually (1). However, given 
the far greater number of scans in the current study, manual segmentation was not practical. 
Therefore, an automated algorithm to quantify EA-CSF and lateral ventricle (LV) volumes 
was developed based on the criteria used in the manual segmentation. (See Supplement for 
details on quantification and validation steps.) Ninety-nine percent of scans met quality 
inspection criteria for inclusion in the final analysis (N=804 scans; Table 2). The automated 
method showed a high correlation with the manual method (ICC=0.80). Figure 1 
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demonstrates an example of the resulting EA-CSF segmentation from the automated 
method.
Statistical Analysis
A longitudinal mixed effects model for repeated measures with unstructured covariance 
matrices was employed to analyze trajectories of EA-CSF and LV volume from 6 to 24 
months of age. This analytic method is suitable for an unbalanced design and allows for 
missing values in a longitudinal study. Independent variables of interest included main effect 
of group, linear effect of age, quadratic effect of age (age2), sex, and group interactions with 
each of these variables. Total cerebral volume (TCV) was included as a covariate given its 
relationship to EA-CSF and LV volumes (1) and to control for possible differences in brain 
size. Scan site was included as another control variable. Following significant omnibus 
results of the primary model described above, Bonferroni-corrected pairwise comparisons 
tested for cross-sectional group differences at each time point (6, 12 and 24 months), and 
estimated marginal means and the pooled standard deviation were generated to compute 
Cohen’s d effect sizes. Percent differences in model-adjusted volumes at each time point and 
Cohen’s d effect sizes are reported relative to the HR-negative group.
A fully cross-validated classification analysis was performed to determine whether EA-CSF 
volume at 6 months could correctly distinguish which infants would be classified with an 
ASD diagnosis at 24 months. The objective of the prediction analysis was to extend beyond 
what can be concluded by the mixed effects model by determining the specificity and 
sensitivity of EA-CSF volume at the single earliest time point (i.e., 6 months of age) to 
separate HR-ASD from HR-negative infants. Only HR infants were included in the 
prediction model to distinguish HR-ASD infants from HR-negative infants using data at 6 
months only. To remain consistent with the primary mixed effects model described above, 
the same covariates were included in the prediction model (sex, age, and TCV at 6 months). 
A 25-fold cross-validation was implemented where 1/25th of the IBIS sample (4%) was left 
out of the prediction model, the model was built (“trained”) on the remaining 96% subjects, 
and then was used to independently predict the 4% – this was repeated 25 times until the 
entire sample had been predicted (via a supervised machine learning classification with a 
balance-boosted trees ensemble algorithm using RUSBoost trees) (53). The overall accuracy 
of the prediction model was reported as the area under the receiver operating characteristic 
curve (AUC), with the corresponding sensitivity and specificity threshold determined by the 
receiver operating characteristic (ROC) curve. 95% confidence intervals for the reported 
proportions (sensitivity, specificity) were calculated according to the efficient-score method 
and corrected for continuity (54). We also performed an out-of-sample validation by using 
this model built on the IBIS data and testing it on the dataset from the original Shen et al. 
(2013) paper on EA-CSF.
Regression analyses (both ordinary least squares and robust regression ROBUSTREG in 
SAS) were generated to test the a priori hypothesis that EA-CSF at 6 months would be 
associated with gross motor ability measured at 6 months within the ASD group. Clinical 
variables of interest included Mullen subscale and Vineland motor scores.
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Group differences in LV volume were tested using the same mixed effects model described 
above, and linear regression was used to test for associations and group interactions between 
LV and EA-CSF at each time point. All tests were two-tailed with α = 0.05. All analyses 
were performed using SAS JMP software (SAS Institute, Cary, NC).
RESULTS
There were no significant group differences in demographic variables (race/ethnicity, 
maternal education level, or family income) (22). There were no significant group 
differences in age at each MRI time point (Table 1). As expected, at 24 months the HR-ASD 
group had significantly lower cognitive ability on the Mullen Early Learning Composite, and 
higher ASD symptom scores on the ADOS (total scores for Social Affect + Repetitive, 
Restricted Behaviors), compared to the two comparison groups (Table 1).
Extra-axial CSF volume
There was a significant negative effect of subject age (age: β=−3.38, F1,483=50.97, 
p<0.0001; age2: β=0.07, F1,486=40.02, p<0.0001) on EA-CSF volume. Total cerebral 
volume was significantly associated with EA-CSF (β=0.05, F1,264=28.51, p<0.0001). There 
was no significant main effect of sex or group x sex interaction (F1,277=0.08, p=0.78; group 
× sex: F2,398=2.46, p=0.09), indicating that EA-CSF did not differ significantly between 
male and female infants after controlling for age and TCV. There were no differences in EA-
CSF by scan site (F3,272=0.11, p=0.96).
High-risk infants who were later diagnosed with ASD had increased EA-CSF at 6 months, 
which remained significantly elevated through 24 months. Specifically, there was a 
significant main effect of group (β=16.01, F2,397=6.04, p=.0026), and no significant group × 
age interactions (group × age: F2,294=2.40, p=0.09; group × age2: F2,274=1.87, p=0.16), 
indicating that the increase in EA-CSF in the HR-ASD group relative to non-ASD groups 
was consistent over the interval studied (covariates included age, age2, TCV, sex, site). 
Direct group comparisons and inspection of the model parameter estimates indicated that, on 
average across the study period, the HR-ASD group had 12.20 cm3 more EA-CSF than the 
HR-negative group (β=12.20; se=3.96; t397=3.08; p=.002) and 12.14 cm3 more EA-CSF 
than the LR-negative group (β=12.14; se=4.10; t397=2.96; p=.003), after controlling for age, 
age2, TCV, sex, and site. There were no differences between the HR-negative and LR-
negative group (β=.06; se=2.11; t397=.03; p=.98). Figure 2 depicts an example of a LR infant 
with a normal level of EA-CSF, compared to a HR infant who had increased EA-CSF at 6, 
12, and 24 months and was diagnosed with ASD at 24 months. (See Supplemental Figure S1 
for example images from representative infants in each group who have EA-CSF volumes 
that are equal to their group’s average.) Figure 3 illustrates the group trajectories of EA-CSF 
from 6–24 months, with percent differences between model-adjusted group means and 
Cohen’s d effect size (relative to the HR-negative group) at each time point. (Individual 
trajectories are shown in supplemental Figure S2.)
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EA-CSF and Subgroups of Autism Severity
To examine whether subgroups with different levels of autism severity were associated with 
differences in EA-CSF volume, the ASD group was stratified into subgroups according to 
well-established, empirically derived categories on the ADOS that index severity of autism 
symptoms (9; 29). There was a significant main effect of group (β=25.77, F3,416=4.99, p=.
002) with the infants with more severe autistic behaviors (ASD-High) having significantly 
greater EA-CSF volume at all time points compared to each of the other groups, including 
the ASD-Moderate, HR-negative, and LR-negative groups (covariates: age, age2, TCV, sex, 
site). Direct group comparisons and inspection of the model parameter estimates revealed 
that, on average across the study period, the ASD-High group had significantly greater EA-
CSF than the ASD-Moderate group (β=19.31; se=8.19; t416=2.36; p=.02), HR-negative 
group (β=22.59; se=6.02; t416=3.75; p=.0002), and LR-negative group (β=22.61; se=6.11; 
t416=3.70; p=.0002), controlling for age, age2, TCV, sex, and site. The ASD-moderate group 
did not differ significantly from the HR-negative (β=3.28; se=5.38; t416=.61; p=.54) and LR-
negative groups (β=3.30; se=5.46; t416=.60; p=.55) in EA-CSF volume. Total cerebral 
volume was significantly associated with EA-CSF (β=0.05, F1,263=29.44, p<0.0001). There 
was no significant main effect of sex (F1,286=.34, p=0.56), indicating that EA-CSF volume 
did not differ between male and female infants after controlling for age and TCV. There was 
a significant group × sex interaction (F3,397=2.87, p=0.04) with the small number of female 
infants in the ASD-High group (n=2 of the 23 in the subgroup) having higher EA-CSF 
volume on average (t397=2.14; p=.03) compared to the male infants in the ASD-High group 
(n=21). Figure 4 illustrates the group trajectories of EA-CSF from 6–24 months, with 
percent differences between model-adjusted group means and Cohen’s d effect size (relative 
to the HR-negative group) at each time point. (Individual trajectories are shown in 
supplemental Figure S3.)
Does EA-CSF at 6 Months Predict Autism Diagnosis at 24 Months?
A fully cross-validated prediction analysis was performed to test whether EA-CSF volume at 
6 months could accurately classify which HR infants would be diagnosed as ASD vs. 
negative for ASD at 24 months. EA-CSF volume at 6 months classified HR-ASD infants at 
an overall accuracy of 69% (AUC=0.69), with corresponding sensitivity of 66% (95% CI: 
50.6–78.7) and specificity of 68% (95% CI: 60.3–74.6). We performed an out-of-sample 
validation on this model, which was built on the current dataset, by testing it on the dataset 
from the original Shen et al. (2013) paper on EA-CSF. The prediction model applied to the 
2013 dataset yielded similar accuracy: overall accuracy of 72%, sensitivity of 80% (95% CI: 
44.2–96.5), and specificity of 67% (95% CI: 38.7–87.0).
EA-CSF Association with Early Motor Skills within the ASD group
Given that motor symptoms are an early emerging feature in infants who develop ASD (7; 9; 
37) and that increased EA-CSF had previously been associated with motor impairments (13–
16), we hypothesized that EA-CSF in early infancy would be related to early motor function 
at 6 months within the HR-ASD group. EA-CSF volume at 6 months was significantly 
correlated with poorer motor skills at 6 months in two measures: the direct examination 
Mullen gross motor subscale (F1,45=11.72, p=.0013; R2=.207; r = −0.46; robust regression: 
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χ2= 12.55, df=1, p=.0004) and the parent-report Vineland motor skills sub scale (F1,45=7.28, 
p=.0098; R2=.134; r = −0.37; robust regression: χ2=11.02, df=1, p=.0009) (Figs. 5A–5B). 
There were no significant correlations between EA-CSF and other Mullen subscales at 6 
months: receptive language (F1,45=.99, p=.3253; R2=.022; r = −0.15; robust: χ2=.56, df=1, 
p=.4540), expressive language (F1,45=1.83, p=.1827; R2=.039; r = 0.20; robust: χ2=1.21, 
df=1, p=.2708), visual reception (F1,45=3.17, p=.0818; R2=.066; r = −0.26; robust: χ2=1.56, 
df=1, p=.2115), or fine motor (F1,45=3.19, p=.0810; R2=.066; r = −0.26; robust: χ2=2.54, 
df=1, p=.1109).
Relationship to Lateral Ventricle Volume
There were no significant group differences in LV volume (F2,383=1.98, p=0.14) or group × 
age interaction (F2,266=1.24, p=0.29). There was a significant negative effect of age on LV 
volume (β=−0.37, F1,602=11.72, p=0.0007). Total cerebral volume was significantly 
associated with LV volume (β=0.02, F1,496=44.34, p<0.0001). There was no significant 
main effect of sex (F1,335=1.43, p=0.23) or group × sex interaction (F2,331=0.20, p=0.82), 
indicating that LV volume did not differ between male and female infants after controlling 
for age and TCV. There were no differences in LV by scan site (F3,320=0.28, p=0.84).
The HR-ASD group did not show a significant correlation between LV and EA-CSF volume 
at 6 months (F1,44 =1.34, p=.25; R2 =.029; r = 0.17), 12 months (F1,28=1.35, p=.25; R2=.
046; r = 0.21), or 24 months (F1,30 =2.54, p=.12; R2 =.078; r=0.28), and the relationship 
between LV and EA-CSF did not differ significantly between groups at any age (group 
interaction at 6 months: F2,335=1.50, p=0.23; 12 months: F2,247=0.004, p=0.99; 24 months: 
F2,201=0.29, p=0.75).
DISCUSSION
In this study, high-risk infants diagnosed with ASD at 24 months had significantly increased 
EA-CSF volume from 6 months through 24 months of age. Differences in EA-CSF volume 
were not accounted for by brain size and were observed in the absence of enlarged 
ventricles. Because of the relatively large sample of infants at risk, it was possible to assess 
whether EA-CSF volume differed among subgroups defined by autism symptom severity. 
Increased EA-CSF volume was more pronounced from 6–24 months in the subgroup of 
infants who had the most severe autistic behaviors at 24 months. These results confirm and 
extend the findings of Shen et al. (1) in an independent sample of infants recruited from 
institutions across the United States, confirming that increased extra-axial CSF is a 
replicable brain anomaly that is detectable as early as 6 months of age and remains elevated 
through 24 months in high-risk infants who go on to develop ASD.
Although increased extra-axial CSF has been observed in the first year of life in the clinical 
radiology literature (10–12), excess CSF is thought to decrease to normal levels in the 
second year. However, longitudinal follow-up with imaging and behavioral assessment is 
rarely conducted (for review, see (38). There have been a few reports linking increased extra-
axial CSF with early motor delay (13–16), and early motor deficits have been widely 
reported in HR infants who later attain a diagnosis of ASD (7; 9; 37; 52). In the present 
study, increased EA-CSF volume at 6 months was associated with poorer motor skills on 
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both direct examination and parent report, supporting the hypothesis that increased EA-CSF 
may affect motor development during the prodromal period in autism, before behaviors 
diagnostic of ASD typically arise.
The question arises as to whether persistently increased EA-CSF indicates a role for 
abnormal CSF circulation in the pathogenesis of ASD or, alternatively, is epiphenomenal 
and indicative of some other underlying process. Excessive CSF in the subarachnoid space, 
in the absence of enlarged ventricles, could be an indication of impaired CSF circulation and 
absorption, which can lead to altered concentration of neural growth factors and potentially 
harmful metabolites that have a pathological effect on normal brain development (21). The 
recent discoveries of the glymphatic and meningeal lymphatic systems of the brain both 
highlight the importance of proper CSF circulation and absorption to clear metabolic 
byproducts from the brain (20; 39; 40). CSF circulation is responsible for the removal of 
potentially neurotoxic waste products and inflammatory cytokines that accumulate in the 
brain (21). For example, amyloid-beta (Aβ) is a neurotoxic protein that is cleared from the 
interstitial and subarachnoid space during CSF circulation and absorption (39). Amyloid-
beta has been found to be elevated in blood, peripheral CSF, and post mortem human brain 
tissue in individuals with ASD (41–45). Evidence of increased Aβ levels in ASD has been 
linked to sleep disturbances (which can disrupt clearance of Aβ) (20), seizures, and deficits 
in motor and cognitive function (41; 42). Altered CSF circulation results in an accumulation 
of metabolic byproducts and an imbalance of inflammatory cytokines and growth factors 
(20; 21), and altered composition of CSF has been shown to have a pathological effect on 
human brain development (18; 19). Future studies, perhaps in animal models of ASD, will 
need to be carried out to evaluate both the underlying causes of persistently increased EA-
CSF and the potential deleterious effects on brain development. While EA-CSF may have a 
pathogenic role in the etiology of ASD, it is also quite possible that increased EA-CSF is a 
marker of some other underlying process that may indicate a more general risk for altered 
neurodevelopment.
There has been recent emphasis placed on the importance of finding biological markers to 
aid in evaluating early risk for neurodevelopmental and other brain-based, behavioral 
disorders (46–48). A major obstacle in this pursuit is the lack of replication of putative 
biomarkers and/or small sample sizes (for review, see (49). The current study addressed both 
concerns, confirming the initial findings in an independent sample roughly seven times 
larger than the first sample. Reproducibility is rare in biomedical research (50), particularly 
in neuroscience (51) and autism (49). This study not only confirms findings in an 
independent sample, but it employed a different image acquisition protocol, multiple 
scanners and study sites, and different (automated) image analysis procedures. The results 
were strikingly similar across both studies, suggesting that the findings are robust. This view 
will be further supported if future studies on independent populations come to similar 
conclusions.
We developed a fully automated method to quantify EA-CSF volume, and the current 
findings suggest that increased EA-CSF is an observable brain anomaly that potentially 
could be quantified using different structural MRI platforms available to clinical 
radiologists. Future studies will determine how these quantitative measurements correspond 
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to qualitative ratings from radiological assessments (22). Before quantification of EA-CSF 
could be useful in a clinical setting, the sensitivity and specificity of predicting autism must 
be established. Increased EA-CSF volume at 6 months had 69% accuracy in predicting 
autism at 24 months. These prediction metrics were similar to those found in the out-of-
sample validation of the previous sample (1), which supports the predictive validity of this 
finding. However, the results of the prediction model are not yet strong enough as a stand-
alone marker to be clinically useful in predicting individual outcomes. Furthermore, the 
specificity of EA-CSF for ASD needs to be evaluated, as it is possible that extra-axial CSF 
may be a more general marker for altered neurodevelopment. Thus, future studies are needed 
to evaluate whether infants with other neurodevelopmental disorders also show increased 
EA-CSF during the first two years of life.
This study raises a number of questions that need to be addressed in order to evaluate what, 
if any, are the potential clinical implications of these findings. Is increased EA-CSF 
associated with ASD only in children at high familial risk, or would it be found more 
generally in other children who develop ASD? Is it specific to autism, or is it present in 
children who develop other neurodevelopmental disorders? What leads to increased EA-
CSF? Is it associated with immunological insults, and are there genetic underpinnings? The 
answers to these questions would contribute to decisions as to whether the presence of 
increased extra-axial CSF should be assessed and monitored routinely in infants at risk for 
ASD. Though the current clinical view is that early increased extra-axial CSF is commonly 
benign and without long-term consequences, this should be re-evaluated in infants at risk for 
ASD in light of the findings of this study and the predecessor study.
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ADOS Autism Diagnostic Observation Schedule
ADI-R Autism Diagnostic Interview -Revised
ASD autism spectrum disorder
AUC area under the receiver operating characteristic curve
EA-CSF extra-axial cerebrospinal fluid
HR high familial risk for ASD
HR-ASD high risk infants later diagnosed with ASD
HR-negative high risk infants who do not develop ASD
LR low familial risk for ASD
LR-negative low risk infants who do not develop ASD
LV lateral ventricles
ROC Receiver operating characteristic
TCV total cerebral volume
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Figure 1. Automated quantification of extra-axial CSF
T1- and T2-weighted images were acquired from each participant and used to segment the 
cerebrospinal fluid in the subarachnoid space between the dura and cortical surface, dorsal 
to the horizontal plane of the anterior-posterior commissure.
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Figure 2. Example brain images indicating the presence of increased extra-axial CSF
(A) T1-weighted coronal images of a low-risk infant with normal MRI at 6, 12, and 24 
months. (B) T1-weighted coronal images of a high-risk infant with increased extra-axial 
CSF at 6, 12, and 24 months. This child was diagnosed with ASD at 24 months.
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Figure 3. Infants later diagnosed with ASD had increased extra-axial CSF by 6 months, which 
remained significantly elevated through 24 months
Note: LS means are adjusted for covariates in model [age, sex, total cerebral volume, scan 
site]. Error bars = ±1 SEM. *p<0.005 vs. HR-negative and vs. LR-negative. Percent 
differences are in relation to the HR-negative group (Cohen’s d).
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Figure 4. ASD subgroup with more severe autism symptoms had a greater increase of extra-axial 
CSF throughout 6-24 months compared to all other groups
The ASD group was stratified into subgroups according to empirically derived categories on 
the ADOS. The ASD subgroup with more severe autism symptoms (HR-ASD-High) had a 
more pronounced increase in extra-axial CSF. Note: LS means are adjusted for covariates in 
model [age, sex, total cerebral volume, scan site]. Error bars = ±1 SEM. **p<0.0005 vs. HR-
negative and vs. LR-negative, p<0.05 vs. HR-ASD-Moderate. Percent differences are in 
relation to the HR-negative group (Cohen’s d).
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Figure 5. Extra-axial CSF is significantly correlated with poorer motor skills in the ASD group
Across the entire HR-ASD group, extra-axial CSF volume at 6 months of age was negatively 
correlated with motor scores at 6 months on the (A) direct examination Mullen gross motor 
subscale (standardized norm of M[SD] = 50[10]); and (B) parent-report Vineland motor 
subscale (standardized norm of M[SD] = 100[15]).
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Table 1
Participant characteristics by diagnostic outcome group
Mean (SD)
High Risk-ASD High Risk-Negative Low Risk-Negative Test statistica
N 47 174 122
Sex 42 M; 5 F 95 M; 79 F 76 M; 46 F X2(2)=21.94, p=1.72 × 10−5
Age at 1st MRI (mo.) 6.6 (.7) 6.6 (.7) 6.7 (.7) F2,340=0.57, p=.57
Age at 2nd MRI (mo.) 12.8 (.7) 12.6 (.6) 12.7 (.8) F2,251=2.14, p=.12
Age at 3rd MRI (mo.) 24.7 (.7) 24.8 (.9) 24.7 (.8) F2,204=0.35, p=.71
Mullen Early Learning Composite (at 
24 mos.)
77.8 (18.6) 102.6 (15.9) 109.8 (13.4) F2,204=46.05, p=3.13 × 10−17 2,204
ADOS Total (at 24 mos.) (Social 
Affect+RRB)
14.2 (5.5) 2.7 (2.3) 2.5 (2.3) F2,204=48.51, p=5.83 × 10−18 2,204
a
Test statistic, degrees of freedom, and p-value of omnibus ANOVA (Age, Mullen, ADOS) and Chi-square test (sex)













Shen et al. Page 21
Table 2
Number of MRI scans at each time point
No. of scans at each time point High-risk ASD High-Risk Negative Low-Risk Negative Total scans at each time point
6 months 47 174 122 343
12 months 31 134 89 254
24 months 32 111 64 207
Total N 110 419 275 804
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